Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study
Tóm tắt
The aim of this cohort study was to investigate the risk of malignant neoplasms and mortality in patients with diabetes treated either with human insulin or with one of three insulin analogues. Data were provided by the largest German statutory health insurance fund (time-frame: January 1998 to June 2005 inclusive), on patients without known malignant disease who had received first-time therapy for diabetes mellitus exclusively with human insulin, aspart, lispro or glargine. The primary outcome was the diagnosis of a malignant neoplasm. Data were analysed by multiple Cox regression models adjusting for potential confounders. A total of 127,031 patients were included, with a mean follow-up time of 1.63 (median 1.41, maximum 4.41) years. A positive association between cancer incidence and insulin dose was found for all insulin types. Because patients receiving combined therapy with insulin analogues and human insulin were excluded, the mean daily dose was much lower for glargine than for human insulin, and a slightly lower cancer incidence in the glargine group was found. After adjusting for dose, a dose-dependent increase in cancer risk was found for treatment with glargine compared with human insulin (p < 0.0001): the adjusted HR was 1.09 (95% CI 1.00 to 1.19) for a daily dose of 10 IU, 1.19 (95% CI 1.10 to 1.30) for a daily dose of 30 IU, and 1.31 (95% CI 1.20 to 1.42) for a daily dose of 50 IU. No increased risk was found for aspart (p = 0.30) or lispro (p = 0.96) compared with human insulin. Considering the overall relationship between insulin dose and cancer, and the lower dose with glargine, the cancer incidence with glargine was higher than expected compared with human insulin. Our results based on observational data support safety concerns surrounding the mitogenic properties of glargine in diabetic patients. Prospective long-term studies are needed to further evaluate the safety of insulin analogues, especially glargine.
Tài liệu tham khảo
Sandhu MS, Dunger DB, Giovannucci EL (2002) Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 94:972–980
Tran TT, Medline A, Bruce WR (1996) Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev 5:1013–1015
Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121:856–862
Larsson SC, Orsini N, Brismar K, Wolk A (2006) Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 49:2819–2823
Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679–1687
Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076–2083
Friberg E, Orsini N, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50:1365–1374
Yang YX, Hennessy S, Lewis JD (2004) Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127:1044–1050
Bornfeldt KE, Gidlöf RA, Wasteson A, Lake M, Skottner A, Arnqvist HJ (1991) Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 34:307–313
Kurtzhals P, Schäffer L, Sørensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005
Mayer D, Shukla A, Enzmann H (2008) Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 114:38–44
Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H (2009) Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 25:41–49
Drejer KK, Sørensen AR, Wiberg FC, Klein HH, Lundemose AG (1992) The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 8:259–285
Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G (2002) Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 21:171–179
Owens DR, Zinman B, Bolli GB (2001) Insulins today and beyond. Lancet 358:739–746
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2007) Kurzwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 1: Abschlussbericht; Auftrag A05-02. [Rapid-acting insulin analogues for the treatment of diabetes mellitus type 1: final report A05-02.] Available from www.iqwig.de/download/A05-02_Abschlussbericht_Kurzwirksame_Insulinanaloga_bei_Diabetes_mellitus_Typ_1.pdf. Accessed 20 March 2009 (article in German)
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2005) Kurzwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 2: Abschlussbericht; Auftrag A05-04. [Rapid-acting insulin analogues for the treatment of diabetes mellitus type 2: final report A05-04.] Available from www.iqwig.de/download/A05-04_Abschlussbericht_Kurzwirksame_Insulinanaloga_bei_Typ_2_Diabetes_mellitus.pdf. Accessed 20 March 2009 (article in German)
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2009) Langwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 2: Abschlussbericht; Auftrag A05-03. [Long-acting insulin analogues for the treatment of diabetes mellitus type 2: final report A05-03.] Available from www.iqwig.de/download/A05-03_Abschlussbericht_Langwirksame_Insulinanaloga_bei_Diabetes_mellitus_Typ_2_V1.1.pdf. Accessed 20 March 2009 (article in German)
Fricke U, Günther J, Zawinell A (2007) Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen für den deutschen Arzneimittelmarkt. Methodik der ATC-Klassifikation und der DDD-Festlegung. ATC-Index mit DDD-Angaben. [The Anatomical Therapeutic Classification with daily doses for the German pharmaceutical market. Methodology of the ATC classification and DDD specification. ATC index with DDD information.] Available from http://wido.de/fileadmin/wido/downloads/pdf_arzneimittel/wido_arz_atc-index_0406.pdf. Accessed 20 March 2009 (article in German)
Hosmer DW, Lemeshow S (1999) Applied survival analysis. Wiley, New York
Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc Ser B 34:187–220
Kleinbaum DG, Klein M (2005) Survival analysis. A self-learning text, 2nd edn. Springer, New York
Bender R, Lange S (2001) Adjusting for multiple testing—when and how? J Clin Epidemiol 54:343–349
Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305
Mühlhauser I, Sawicki PT, Blank M, Overmann H, Richter B, Berger M (2002) Reliability of causes of death in persons with type I diabetes. Diabetologia 45:1490–1497
Horvath K, Jeitler K, Berghold A et al (2007) Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev (2):CD005613. doi:10.1002/14651858.CD005613.p
Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H (2009) Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 180:385–397